BioInvent International
Develops first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BioInvent International is a clinical-stage biotechnology company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates from its proprietary antibody library. BioInvent's primary focus is advancing its diversified clinical pipeline, which features drug candidates targeting unique mechanisms of action and novel targets like FcγRIIb and TNFR2. The company manages its development risks through stringent portfolio management and strategic partnerships with major pharmaceutical firms to develop transformative treatments for cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-02 10:10 |
Board/Management Information
BioInvent Announces Board of Directors Update
|
English | 67.9 KB | ||
| 2025-09-02 10:10 |
Board/Management Information
BioInvent offentliggör förändring i styrelsen
|
Swedish | 67.3 KB | ||
| 2025-08-26 08:30 |
Interim Report
|
Swedish | 3.1 MB | ||
| 2025-08-26 08:30 |
Interim Report
|
English | 3.0 MB | ||
| 2025-08-26 08:29 |
Regulatory News Service
BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical …
|
English | 82.3 KB | ||
| 2025-08-26 08:29 |
Regulatory News Service
BioInvent gör strategiska portföljförändringar för att accelerera ledande klini…
|
Swedish | 82.1 KB | ||
| 2025-06-12 09:00 |
Earnings Release
BioInvent presenterar lovande fas 2a-monoterapidata för BI-1808 i CTCL på EHA 2…
|
Swedish | 82.1 KB | ||
| 2025-06-12 09:00 |
Regulatory News Service
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at E…
|
English | 82.1 KB | ||
| 2025-05-27 14:00 |
M&A Activity
XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInve…
|
Swedish | 89.3 KB | ||
| 2025-05-27 14:00 |
M&A Activity
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInve…
|
English | 90.2 KB | ||
| 2025-05-14 15:30 |
Regulatory News Service
BioInvent presenterar ytterligare fas 2a-data för BI-1808 monoterapi i CTCL på …
|
Swedish | 81.5 KB | ||
| 2025-05-14 15:30 |
Regulatory News Service
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, ri…
|
English | 81.8 KB | ||
| 2025-05-14 15:30 |
Earnings Release
Uppdatering från BioInvents fas 2a-trippelkombinationsstudie med BI-1206, ritux…
|
Swedish | 81.9 KB | ||
| 2025-05-14 15:30 |
Regulatory News Service
BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA…
|
English | 80.8 KB | ||
| 2025-04-29 17:01 |
Post-Annual General Meeting Information
Beslut på BioInvents årsstämma 2025
|
Swedish | 71.8 KB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
